Search Results - "Sklarin, N T"

Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer by Baselga, J, Tripathy, D, Mendelsohn, J, Baughman, S, Benz, C C, Dantis, L, Sklarin, N T, Seidman, A D, Hudis, C A, Moore, J, Rosen, P P, Twaddell, T, Henderson, I C, Norton, L

“…The HER2/neu proto-oncogene is overexpressed in 25% to 30% of patients with breast cancer. Trastuzumab (Herceptin; Genentech, San Francisco, CA), a recombinant…”
Get more information

Metastatic Lobular Carcinoma of the Breast: Patterns of Spread in the Chest, Abdomen, and Pelvis on CT by Winston, Corinne B, Hadar, Orna, Teitcher, Jerrold B, Caravelli, James F, Sklarin, Nancy T, Panicek, David M, Liberman, Laura

“…We determined the pattern of spread of metastatic lobular carcinoma in the chest, abdomen, and pelvis on CT. We identified 57 women (age range, 30-79 years;…”
Get full text

Spontaneous recurrent tumor lysis syndrome in breast cancer by Sklarin, N T, Markham, M

“…A case of spontaneous recurrent acute tumor lysis syndrome is presented in a woman with inflammatory breast cancer. The occurrence of tumor lysis syndrome in…”
Get more information

Sources of anticipatory emotional distress in women receiving chemotherapy for breast cancer by DiLorenzo, T A, Jacobsen, P B, Bovbjerg, D H, Chang, H, Hudis, C A, Sklarin, N T, Norton, L

“…The contribution of classical conditioning processes to patients' distress before chemotherapy infusions (anticipatory distress) was compared to other…”
Get more information

Metastatic placental lymphoma associated with maternal human immunodeficiency virus infection by Pollack, R N, Sklarin, N T, Rao, S, Divon, M Y

“…Pregnancy complicated by maternal human immunodeficiency virus (HIV) infection is increasing in frequency. This report describes a maternal malignancy…”
Get more information

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer by Baselga, J, Tripathy, D, Mendelsohn, J, Baughman, S, Benz, C C, Dantis, L, Sklarin, N T, Seidman, A D, Hudis, C A, Moore, J, Rosen, P P, Twaddell, T, Henderson, I C, Norton, L

“…Breast cancer frequently overexpresses the product of the HER2 proto-oncogene, a 185-kd growth factor receptor (p185HER2). The recombinant humanized monoclonal…”
Get more information

Augmentation of activity of cis-diamminedichloroplatinum(II) and mitomycin C by interferon in human malignant mesothelioma xenografts in nude mice by SKLARIN, N. T, CHAHINIAN, A. P, FEUER, E. J, LAHMAN, L. A, SZRAJER, L, HOLLAND, J. F

“…Two human mesothelioma xenograft lines, BG and ES, serially passaged in athymic mice, were studied to determine the efficacy of alpha-interferon in this type…”
Get full text

A phase I trial and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumors by SKLARIN, N. T, LATHIA, C. D, BENSON, L, GROVE, W. R, THOMAS, S, ROCA, J, EINZIG, A. I, WIERNIK, P. H

“…CI-980 is a synthetic mitotic inhibitor that binds to the colchicine binding site of tubulin. It demonstrates broad activity against human and murine tumor…”
Get full text

Vibrio parahaemolyticus Septicemia in a Patient with Neutropenic Leukemia by Dobroszycki, Joanna, Sklarin, Nancy T., Szilagy, George, Tanowitz, Herbert B.

“…Vibrio parahaemolyticus, usually associated with gastrointestinal infections following ingestion of seafood, is occasionally isolated from extraintestinal…”
Get full text

Lymphomas following cardiac transplantation. Case report and review of the literature by Sklarin, N T, Dutcher, J P, Wiernik, P H

“…The success of allogeneic organ transplantation is in great part due to pharmacologic advances in the area of immunosuppressive therapy. However, this…”
Get more information

Mitoxantrone and hepatic toxicity by Paciucci, P A, Sklarin, N T

Get more information

A phase II trial of CI-921 in advanced malignancies by SKLARIN, N. T, WIERNIK, P. H, JOLIVET, J, RUCKDESCHEL, J. C, ROBERT, N. J, VELEZ-GARCIA, E, BERGSAGEL, D. E, PANASCI, L. C, VAN DER MEWE, A. M, LONGUEVILLE, J. J, LEIBY, J, KOWAL, C. D, GROVE, W. R, BENSON, L, MITTELMAN, A, MAROUN, J. A, STEWART, J. A, ROBERT, F, DOROSHOW, J. H, ROSEN, P. J

“…CI-921, (9-[[2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino]- N,5-dimethyl-4-acridinecarboxamide 2-hydroxyethanesulfonate (1:1)), an anilinoacridine…”
Get full text

Adjuvant radiotherapy for breast cancer as a risk factor for the development of lung cancer by WIERNIK, P. H, SKLARIN, N. T, DUTCHER, J. P, SPARANO, J. A, GREENWALD, E. S

“…Women diagnosed with primary breast or lung cancer and recorded between 1972 and 1989 in our tumor registry were identified. Of 4,123 lung cancer patients and…”
Get full text

Incidence of hypersensitivity reactions (HSRs) to albumin-bound paclitaxel (ABI) in patients (pts) with a history of HSR to cremophor-based paclitaxel (P) by Timoney, J. P., McGuffy, D., DeRitis, D., Tyler, E., Sumka, J., Pozotrigo, M., Bhatt, V., Chan, A., Sklarin, N. T.

“…Abstract only…”
Get full text

Pathologic features and outcomes of pregnancy-associated breast cancer (PABC): A case control study by Murphy, C., Mallam, D., Stein, S., Patil, S., Howard, J., Sklarin, N. T., Gemignani, M., Hudis, C., Seidman, A. D.

“…Abstract only…”
Get full text

Correlative biomarkers in a phase II study of dasatinib (D) and weekly (w) paclitaxel (P) for patients (Pts) with metastatic breast carcinoma (MBC) by Morris, P. G., Chang, J. C., Abbruzzi, A., Patil, S., Modi, S., Seidman, A. D., Sklarin, N. T., Norton, L., Hudis, C., Fornier, M. N.

“…Abstract only…”
Get full text

TBCRC 011: Targeting the androgen receptor (AR) for the treatment of AR+/ER-/PR- metastatic breast cancer (MBC) by Gucalp, A., Tolaney, S. M., Isakoff, S. J., Ingle, J. N., Liu, M. C., Carey, L. A., Blackwell, K. L., Rugo, H. S., Nabell, L., Abbruzzi, A., Gonzalez, J., Giri, D. D., Patil, S., Feigin, K., D'Andrea, G., Theodoulou, M., Drullinsky, P., Sklarin, N. T., Hudis, C., Traina, T. A.

“…Abstract only…”
Get full text

MSKCC Quality Assessment (QA) monitoring program for potentially harmful chemotherapy orders by Sklarin, N. T., Timoney, J., Kampel, L., Hydzik, C., Savage, J., Capobianco, M., Miransky, J., Haspel, J.

“…Abstract only…”
Get full text

MSKCC Quality Assessment (QA) monitoring program for potentially harmful chemotherapy orders by Sklarin, N. T., Timoney, J., Kampel, L., Hydzik, C., Savage, J., Capobianco, M., Miransky, J., Haspel, J.

“…Abstract only…”
Get full text

Trastuzumab 6 mg/kg and 4 mg/kg can be infused safely over 30 minutes by Chan, AS, Freeswick, S, Sklarin, NT

“…Abstract Abstract #3150 Background: Trastuzumab (T) is a humanized monoclonal antibody used in the treatment of breast cancers which overexpress the HER2…”
Get full text